Concurrent vitiligo and atopic dermatitis successfully treated with upadacitinib: a case report.

This letter to the editor discusses the successful treatment of a 16-year-old boy with concurrent vitiligo and atopic dermatitis using the JAK inhibitor upadacitinib. The article explains that vitiligo is a depigmentation disorder caused by the destruction of melanocytes, and atopic dermatitis is characterized by a type 2 immune response. The authors suggest that there may be a potential association between vitiligo and atopic dermatitis due to overlapping genetic and immune mechanisms. The patient in the case study experienced repigmentation and relief from symptoms after treatment with upadacitinib. The authors conclude that upadacitinib can be an effective treatment option for patients with both vitiligo and atopic dermatitis. [Extracted from the article]